Compare EIG & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | VTYX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.0M | 990.9M |
| IPO Year | 2006 | 2021 |
| Metric | EIG | VTYX |
|---|---|---|
| Price | $39.59 | $13.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 264.8K | ★ 3.6M |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 40.30 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.76 | N/A |
| P/E Ratio | $86.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $0.90 |
| 52 Week High | $51.23 | $15.34 |
| Indicator | EIG | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 72.58 |
| Support Level | $38.29 | $13.89 |
| Resistance Level | $43.30 | $14.07 |
| Average True Range (ATR) | 1.59 | 0.03 |
| MACD | -0.13 | -0.11 |
| Stochastic Oscillator | 31.51 | 88.89 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.